A mouse model of Jansen's metaphyseal chondrodysplasia for investigating disease mechanisms and candidate therapeutics
- PMID: 40455993
- PMCID: PMC12167993
- DOI: 10.1073/pnas.2500176122
A mouse model of Jansen's metaphyseal chondrodysplasia for investigating disease mechanisms and candidate therapeutics
Abstract
Jansen's metaphyseal chondrodysplasia (JMC) is a rare disorder caused by activating mutations in the parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor (PTH1R). Patients exhibit short stature, dysmorphic bones, and severe growth plate abnormalities, as well as hypercalcemia, hypercalciuria, hypophosphatemia, and reduced plasma PTH levels. Humanized PTH1R (hPTH1R) mice expressing the H223R-hPTH1R JMC mutation die early without breeding. We therefore generated and characterized a stable mouse line expressing the T410R-hPTH1R allele, which confers a milder disease phenotype in patients. Mutant mice show near-normal longevity and reproductive capacity yet exhibit a profound skeletal phenotype characteristic of the disease. The long bones of T410R mice are markedly misshapen and have expanded metaphyses with disarrayed chondrocyte zones in growth plates and reduced primary spongiosa. PET/CT scanning revealed diminished uptake of [18F]-sodium fluoride in the growth plate area, consistent with reduced mineralization and vascularization. Genetic ablation of Hdac4 rescued the growth plate abnormalities in T410R mice, thereby establishing the PTH1R-Gαs-cAMP-PKA-SIK3-HDAC4/5 pathway as the main mediator of growth plate abnormalities in JMC. Serum calcium was elevated and endogenous PTH was suppressed in T410R mice, and both parameters could be normalized by acute injection of an optimized PTH inverse agonist peptide. The T410R mouse thus represents a stable animal model of JMC that recapitulates the abnormalities in skeletal development and mineral ion homeostasis which characterize this disease. The mice should help efforts to further define the cellular and molecular mechanisms underlying the JMC phenotype and to develop a potential mode of therapy.
Keywords: Jansen’s metaphyseal chondrodysplasia; PTH; PTH receptor; PTHrP; chondrocytes.
Conflict of interest statement
Competing interests statement:S.H.G. is a cofounder of Longevity Biotech, Inc., which is pursuing biomedical applications of α/β-peptides. H.M.K. consults for Chugai Pharma, though noneof that consultation involves the topics of this manuscript. M.N.W. is an inventor on pending patents regarding SIK inhibitors, receives research funding from Nimbus Therapeutics, and serves as a consultant for Relation Therapeutics, Sitryx Therapeutics, Aditum Bio, and GLG. None of these activities are directly related to this research. M.T.C. co-authored a 2022 review with Dr. Michael Whyte.
Comment in
-
Humanized mice to model rare human diseases.Proc Natl Acad Sci U S A. 2025 Jun 24;122(25):e2512731122. doi: 10.1073/pnas.2512731122. Epub 2025 Jun 16. Proc Natl Acad Sci U S A. 2025. PMID: 40523196 No abstract available.
References
-
- Kronenberg H. M., Developmental regulation of the growth plate. Nature 423, 332–336 (2003). - PubMed
-
- Kronenberg H. M., PTHrP and skeletal development. Ann. N.Y. Acad. Sci. 1068, 1–13 (2006). - PubMed
-
- John Martin T., Parathyroid hormone-related protein, its regulation of cartilage and bone development, and role in treating bone diseases. Physiol. Rev. 96, 831–871 (2016). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials